Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects

Although cancer-therapy-related cardiac dysfunction (CTRCD) is a critical issue in clinical practice, there is a glaring lack of evidence regarding cardiotoxicity management. To determine an effective and suitable dosage of treatment using angiotensin receptor–neprilysin inhibitors (ARNI) with sodiu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Donghyun, Jang, Gyuho, Hwang, Jaetaek, Wei, Xiaofan, Kim, Hyunsoo, Son, Jinbae, Rhee, Sang-Jae, Yun, Kyeong-Ho, Oh, Seok-Kyu, Oh, Chang-Myung, Park, Raekil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788442/
https://www.ncbi.nlm.nih.gov/pubmed/36559124
http://dx.doi.org/10.3390/pharmaceutics14122629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788442/
https://www.ncbi.nlm.nih.gov/pubmed/36559124
http://dx.doi.org/10.3390/pharmaceutics14122629

Ejemplares similares